Skip to main content

Table 3 IECV results for risk (of cure) prediction based on the main effects model as derived from IPD of ten trials

From: Prognosis and prediction of antibiotic benefit in adults with clinically diagnosed acute rhinosinusitis: an individual participant data meta-analysis

 

C-statistic

R2

Brier

Intercept

Slope

Bucher

0.59

0.02

0.21

0.08

0.79

De Sutter

0.55

−0.49

0.30

−0.82

0.38

Kaiser

0.55

−0.60

0.33

0.61

0.38

Meltzer

0.62

0.03

0.21

0.00

1.57

Merenstein

0.57

−0.26

0.29

−0.51

0.57

Schering-Plough

0.58

0.02

0.22

0.15

0.88

Stalman

0.59

0.04

0.22

−0.04

0.92

Varonen

0.62

−0.27

0.21

0.94

1.09

Williamson1

0.60

0.01

0.23

0.09

0.67

Williamson2

0.62

0.04

0.22

−0.10

1.04

  1. IECV Internal-external cross-validation